ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer—the first interim results from the OPTIMISE study

References

• Zeineddine FA, Zeineddine MA, Yousef A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023;7(1):16. doi: 10.1038/s41698-023-00353-4.
   PubMed Web of Science ®Google Scholar
• Mise Y, Imamura H, Hashimoto T, et al. Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases. Ann Surg. 2010;251(5):902–909. doi: 10.1097/SLA.0b013e3181c9868a.
   PubMed Web of Science ®Google Scholar
• Serrano PE, Gu CS, Husien M, et al. Risk factors for survival following recurrence after first liver resection for colorectal cancer liver metastases. J Surg Oncol. 2019;120(8):1420–1426. doi: 10.1002/jso.25735.
   PubMed Web of Science ®Google Scholar
• Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26(30):4906–4911. doi: 10.1200/JCO.2008.17.3781.
   PubMed Web of Science ®Google Scholar
• Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022;14:17588359221133171. doi: 10.1177/17588359221133171.
   Web of Science ®Google Scholar
• Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127–134. doi: 10.1038/s41591-022-02115-4.
   PubMed Web of Science ®Google Scholar
• Boysen AK, Pallisgaard N, Andersen CSA, et al. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer. Acta Oncol. 2020;59(12):1424–1429. doi: 10.1080/0284186X.2020.1806357.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II Colon cancer. N Engl J Med. 2022;386(24):2261–2272. doi: 10.1056/NEJMoa2200075.
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Chun YS, Overman MJ, et al. Effect of Co-mutation of RAS and TP53 on postoperative ctDNA detection and early recurrence after hepatectomy for colorectal liver metastases. J Am Coll Surg. 2022;234(4):474–483. doi: 10.1097/XCS.0000000000000093.
   PubMed Web of Science ®Google Scholar
• Newhook TE, Overman MJ, Chun YS, et al. Prospective study of perioperative circulating tumor DNA dynamics in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2022;277(5):813–820. doi: 10.1097/SLA.0000000000005461.
   Web of Science ®Google Scholar
• Lonardi S, Nimeiri H, Xu C, et al. Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: an exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection. Int J Mol Sci. 2022;23:1–13.
   Web of Science ®Google Scholar
• Marmorino F, Prisciandaro M, Giordano M, et al. Circulating tumor DNA as a marker of minimal residual disease after radical resection of colorectal liver metastases. J Clin Oncol Precis Oncol. 2022;6:e2200244.
   PubMed Web of Science ®Google Scholar
• van 't Erve I, Medina JE, Leal A, et al. Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells. Clin Cancer Res. 2023;29(5):899–909. doi: 10.1158/1078-0432.CCR-22-2538.
   PubMed Web of Science ®Google Scholar
• Mason MC, Tzeng C-WD, Tran Cao HS, et al. Preliminary analysis of liquid biopsy after hepatectomy for colorectal liver metastases. J Am Coll Surg. 2021;233(1):82–89. doi: 10.1016/j.jamcollsurg.2021.02.011.
   PubMedGoogle Scholar
• Tie J, Wang Y, Cohen J, et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study. PLoS Med. 2021;18(5):e1003620. doi: 10.1371/journal.pmed.1003620.
   PubMed Web of Science ®Google Scholar
• Wang D-S, Yang H, Liu X-Y, et al. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Theranostics. 2021;11(14):7018–7028. doi: 10.7150/thno.59644.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. J Clin Oncol Precis Oncol. 2021;5:1166–1177. doi: 10.1200/PO.21.00101.
   Web of Science ®Google Scholar
• Bolhuis K, van 't Erve I, Mijnals C, et al. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. EBioMedicine. 2021;70:103498. doi: 10.1016/j.ebiom.2021.103498.
   PubMed Web of Science ®Google Scholar
• Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586–5594. doi: 10.1158/1078-0432.CCR-21-0410.
   PubMed Web of Science ®Google Scholar
• Reinert T, Petersen LMS, Henriksen TV, et al. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases. Int J Cancer. 2022;150(9):1537–1548. doi: 10.1002/ijc.33924.
   PubMed Web of Science ®Google Scholar
• Øgaard N, Reinert T, Henriksen TV, et al. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: a prospective cohort study. Eur J Cancer. 2022;163:163–176. doi: 10.1016/j.ejca.2021.12.026.
   PubMed Web of Science ®Google Scholar
• Callesen LB, Hansen TF, Andersen RF, et al. OPTIMISE: optimisation of treatment selection and follow-up in oligometastatic colorectal cancer: a ctDNA-guided phase II randomised approach. Study protocol. Acta Oncol. 2022;61(9):1152–1156. doi: 10.1080/0284186X.2022.2116728.
   PubMed Web of Science ®Google Scholar
• Pallisgaard N, Spindler KLG, Andersen RF, et al. Controls to validate plasma samples for cell free DNA quantification. Clin Chim Acta. 2015;446:141–146. doi: 10.1016/j.cca.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Roperch JP, Incitti R, Forbin S, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13(1):566. doi: 10.1186/1471-2407-13-566.
   PubMedGoogle Scholar
• Lefèvre AC, Pallisgaard N, Kronborg C, et al. The clinical value of measuring circulating HPV DNA during chemo-radiotherapy in squamous cell carcinoma of the anus. Cancers (Basel). 2021;13(10):2451. doi: 10.3390/cancers13102451.
   PubMed Web of Science ®Google Scholar
• Peeters M, Kafatos G, Taylor A, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials. Eur J Cancer. 2015;51(13):1704–1713. doi: 10.1016/j.ejca.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Thomsen CB, Andersen RF, Lindebjerg J, et al. Correlation between tumor-specific mutated and methylated DNA in colorectal cancer. J Clin Oncol Precis Oncol. 2019;3:1–8. doi: 10.1200/PO.18.00162.
   PubMed Web of Science ®Google Scholar
• Thomsen CB, Hansen TF, Andersen RF, et al. Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. Ther Adv Med Oncol. 2020;12:1758835920918472. doi: 10.1177/1758835920918472.
   Web of Science ®Google Scholar
• Raunkilde L, Hansen TF, Andersen RF, et al. NPY gene methylation in circulating tumor DNA as an early biomarker for treatment effect in metastatic colorectal cancer. Cancers (Basel). 2022;14(18):4459. doi: 10.3390/cancers14184459.
   PubMed Web of Science ®Google Scholar